Table 1.
Clinicopathological characteristics of 329 patients with NMIBC stratified by EORTC-GUCG risk group
| All patients (n=329) | Low risk (n=31) | Intermediate risk (n=189) | High risk (n=109) | p-value | |
|---|---|---|---|---|---|
| Gender, n (%) | |||||
| Male/female | 262 (79.6)/67 (20.4) | 23 (74.2)/8 (25.8) | 148 (78.3)/41 (21.7) | 91 (83.5)/18 (16.5) | 0.413 |
| Age (years) | |||||
| Mean ± SD | 62.90±12.50 | 58.32±12.98 | 61.76±12.98 | 66.16±10.75 | 0.001 |
| Median (range) | 63 (28–89) | 66 (28–88) | 63.5 (32–89) | 67 (32–85) | |
| History of smoking, n (%) | |||||
| Yes | 93 (28.3) | 11 (35.5) | 53 (28.0) | 29 (26.6) | 0.622 |
| No | 236 (71.7) | 20 (64.5) | 136 (72.0) | 80 (73.4) | |
| Symptoms, n (%) | |||||
| Positive | 259 (78.1) | 23 (74.2) | 140 (74.1) | 96 (88.1) | 0.014 |
| Negative | 70 (21.9) | 8 (25.8) | 49 (25.9) | 13 (11.9) | |
| Tumor focality, n (%) | |||||
| Unifocal | 206 (62.6) | 31 (100.0) | 107 (56.6) | 68 (62.4) | 0.272 |
| Multifocal | 123 (37.4) | 0 (0.0) | 82 (43.4) | 41 (37.6) | |
| Tumor size, n (%) | |||||
| ≤1 cm | 61 (18.6) | 11 (35.5) | 37 (19.6) | 13 (11.9) | <0.001 |
| 1–3 cm | 155 (47.1) | 20 (64.5) | 84 (44.4) | 51 (46.8) | |
| ≥3 cm | 113 (34.3) | 0 (0.0) | 68 (36.0) | 45 (41.3) | |
| Tumor grade, n (%) | |||||
| G1 | 55 (16.7) | 31 (100.0) | 24 (12.7) | 0 (0.0) | <0.001 |
| G2 | 189 (57.5) | 0 (0.0) | 165 (87.3) | 0 (0.0) | |
| G3 | 85 (25.8) | 0 (0.0) | 0 (0.0) | 85 (100.0) | |
| Pathological T stage, n (%) | |||||
| pTa | 247 (75.1) | 31 (100.0) | 189 (100.0) | 27 (24.8) | <0.001 |
| pT1 | 82 (24.9) | 0 (0.0) | 0 (0.0) | 82 (75.2) | |
Abbreviations: NMIBC, non-muscle-invasive bladder cancer; EORTC-GUCG, European Organization for the Research and Treatment of Cancer; SD, standard deviation.